After AbbVie took bretisilocin, what’s next for Gilgamesh Pharma’s neuropsychiatric pipeline?

When AbbVie acquired bretisilocin from Gilgamesh Pharmaceuticals in a deal worth up to USD 1.2 billion, the headlines focused on what AbbVie was gaining: a short-acting antidepressant with fast-track potential in outpatient psychiatry. But behind the scenes, another significant development was unfolding. Gilgamesh didn’t just sell a compound—it restructured its entire business. Under the terms of the transaction, Gilgamesh spun out its remaining programs into a newly formed entity, Gilgamesh Pharma Inc. This new company retains the scientific core and intellectual property pipeline, while bretisilocin now belongs to AbbVie.

This structural split has created two strategic tracks. AbbVie takes the de-risked, late-stage compound with commercial potential. Gilgamesh Pharma retains the early-stage risk, but also the full upside of assets still in the discovery and clinical validation phase. In the context of modern biotech and neuropsychiatric drug development, this spin-out strategy represents a smart recalibration. Rather than go all-in on one asset or get swallowed whole, Gilgamesh has effectively turned itself into an innovation engine with optionality, platform leverage, and focus.

What does Gilgamesh Pharma retain post-acquisition—and how differentiated are these assets?

Post-deal, Gilgamesh Pharma Inc. is emerging with a portfolio of psychedelic-adjacent and neuroplasticity-focused psychiatric therapies that sit at the intersection of novel mechanism design and scalable treatment delivery. Key among these retained programs is blixeprodil, an oral NMDA receptor antagonist that has completed a Phase 1 trial and is now in a Phase 2a study for major depressive disorder. NMDA antagonists have gained attention since the approval of esketamine, but blixeprodil appears to be designed with a differentiated receptor profile and potentially improved tolerability.

In addition to blixeprodil, Gilgamesh Pharma is advancing a class of proprietary ibogaine analogs. Classic ibogaine is known for its rapid-acting anti-addiction effects but is limited by cardiotoxicity and complex hallucinogenic profiles. Gilgamesh’s analogs aim to retain therapeutic benefits while avoiding safety concerns. These compounds could target both depression and substance use disorders—a dual pathway with significant commercial upside.

The third prong in Gilgamesh’s retained arsenal is its M1/M4 muscarinic receptor agonist program. This targets cognitive and negative symptoms in schizophrenia, an area where traditional antipsychotics have consistently failed. The muscarinic pathway has resurfaced as a promising mechanism, and Gilgamesh is one of only a handful of private companies investing in precision agonists with psychiatric indications.

Taken together, the retained pipeline reflects a diversified portfolio that is not tied to classical psychedelics, but instead focuses on scalable, rapid-acting interventions that could compete with or complement existing standards like SSRIs, ketamine, and antipsychotics.

Why Gilgamesh Pharma’s structure offers strategic flexibility for biotech investors and pharma partners

By spinning out its early-stage pipeline while monetizing its most clinically mature asset, Gilgamesh has created a capital-light model that maintains strategic flexibility. Unlike single-asset companies that are forced to fund Phase 3 trials to retain value, Gilgamesh Pharma can prioritize preclinical and Phase 1/2 development with optionality for partnerships or further spin-outs.

This model also positions Gilgamesh Pharma as a prime candidate for platform-building or bolt-on acquisition by other neuroscience-focused companies. Because the 2024 collaboration and licensing agreement with AbbVie transfers to the new entity, Gilgamesh Pharma retains the commercial channel to re-engage with AbbVie on future assets. That relationship provides both validation and exit visibility—two factors that biotech investors increasingly demand in post-pandemic capital environments.

At a time when many psychedelic startups are struggling to convert early hype into tangible progress, Gilgamesh Pharma’s reset positions it to be a rational, data-first player in the next phase of neuropsychiatry innovation. The portfolio is structured for non-overlapping indications and mechanisms, which gives the company latitude to pivot or partner depending on regulatory trends and clinical readouts.

What challenges remain in Gilgamesh Pharma’s pursuit of pipeline maturation?

Despite its structural strengths, Gilgamesh Pharma faces the same challenges as any early-stage neuroscience company. The field is high-risk, capital-intensive, and often slow-moving from preclinical success to regulatory approval. Even as investor sentiment improves for mental health-focused biotech, the path from IND to New Drug Application remains filled with regulatory ambiguity—especially for novel mechanisms like ibogaine analogs or muscarinic agonists.

There are also biological and translational unknowns. While NMDA receptor antagonists have shown promise, not all compounds in this class succeed. Cardiovascular safety remains a gating factor for ibogaine-inspired compounds, and muscarinic agents require tight pharmacological precision to avoid cognitive or motor side effects. The broader industry has learned that mechanistic promise does not always equal commercial or regulatory feasibility.

On the capital front, Gilgamesh Pharma will need to secure funding to advance its programs through Phase 2, and in today’s market, non-dilutive financing or strategic partnerships may be essential. The company’s long-term success will depend on its ability to generate high-quality data, de-risk its programs clinically, and attract commercial interest without losing control of its pipeline.

How Gilgamesh’s reset reflects a maturing model for psychedelic-adjacent biotech

The emergence of Gilgamesh Pharma as a post-deal spin-out mirrors a shift in how the psychedelic and neuroplasticity drug sector is evolving. In 2020–2022, the market was dominated by early IPOs and bold claims around psilocybin, MDMA, and LSD analogs. But by 2025, the tone has changed. Investors and pharmaceutical companies now prefer short-acting, outpatient-compatible molecules that can realistically be integrated into psychiatry workflows.

Gilgamesh Pharma’s pipeline aligns with this new reality. The company is not betting on long-duration hallucinogenic experiences but is focused on pharmacologies that combine neural circuit engagement with real-world treatment practicality. This makes it better aligned with health system realities and payer expectations.

The structural clarity of the spin-out model also signals that biotech companies are adopting more strategic financing and exit frameworks. Instead of building bloated verticals, companies like Gilgamesh are structuring around clinical inflection points, retaining ownership of early-stage risk while externalizing late-stage commercialization to partners like AbbVie.

What to watch over the next 12–18 months as Gilgamesh Pharma matures

Looking ahead, the market will be watching several key developments. First, results from the Phase 2a trial of blixeprodil in depression will be critical to validate Gilgamesh Pharma’s clinical platform. A positive readout could open the door for licensing interest or Series B funding. Second, preclinical progression of the ibogaine and muscarinic programs into IND-enabling studies will signal pipeline momentum.

The company may also explore additional licensing agreements or strategic alliances, particularly with larger pharma firms looking to enter the neuroplasticity space. Given that AbbVie already has a collaboration framework in place, it would not be surprising if a second deal emerges should one of the retained programs reach proof-of-concept.

Gilgamesh’s ability to navigate early development without excessive dilution, while still maintaining trial velocity, will be a key differentiator in a competitive field. Other players in this space—such as Delix Therapeutics, MindMed, and Bright Minds Biosciences—are also advancing non-hallucinogenic psychiatric compounds, making execution and focus essential.

Why Gilgamesh Pharma could be one of the most important players in the next wave of psychiatric drug innovation

While AbbVie now holds bretisilocin, the next story may belong to Gilgamesh Pharma. The company has restructured around a portfolio that reflects both deep scientific thinking and strategic pragmatism. Its assets span mechanistically diverse targets, from NMDA to muscarinic to serotonergic pathways, and its development horizon is paced for optionality—not forced acceleration.

For investors, analysts, and pharma partners tracking the mental health and psychedelics sector, Gilgamesh Pharma represents the next test case for what a post-IPO, post-hype neuropsychiatric biotech looks like. If the company can show that it can move first-in-class assets through Phase 2 efficiently and align with scalable treatment models, it could become not just a player—but a blueprint.

What key takeaways should investors and pharma partners know about Gilgamesh Pharma’s next steps?

• Gilgamesh Pharmaceuticals sold bretisilocin to AbbVie for up to USD 1.2 billion and spun out its remaining pipeline into a new entity, Gilgamesh Pharma Inc.
• The spin-out retains key neuropsychiatric programs, including blixeprodil (an NMDA antagonist), safer ibogaine analogs for addiction and depression, and M1/M4 muscarinic receptor agonists targeting schizophrenia and cognition.
• Gilgamesh Pharma preserves its 2024 collaboration and licensing agreement with AbbVie, maintaining strategic optionality for future deals.
• The company’s portfolio is now positioned around scalable, rapid-acting psychiatric therapies rather than classical psychedelics, aligning with payer and health system demands.
• By exiting its late-stage asset and focusing on early-stage innovation, Gilgamesh Pharma follows a capital-efficient biotech model increasingly favored in the psychiatric therapeutics space.
• Key milestones in the next 12–18 months include Phase 2a data for blixeprodil, IND-enabling studies for ibogaine and muscarinic programs, and potential new licensing partnerships.
• Gilgamesh Pharma’s success will depend on its ability to deliver proof-of-concept data, secure non-dilutive funding or strategic alliances, and stay competitive in the maturing psychedelic-adjacent CNS sector.